##### 



ONCOGEL/GENEXOL
RESTATED LICENSE AND SUPPLY AGREEMENT
 JUNE 20th




---



##### 



TABLE OF CONTENTS
 RECITALS
    
    
    1Section 1 Definitions
    
    
    2Section 2 Product and Trademark License
    
    
    4Section 3 Royalties
    
    
    4Section 4 Accounting Records
    
    
    6Section 5 Product Development and Marketing
    
    
    6Section 6 Genexol Supply
    
    
    8Section 7 Technology Ownership and Maintenance
    
    
    12Section 8 Representations and Warranties of MacroMed
    
    
    12Section 9 Representations and Warranties of Genex
    
    
    12Section 10 Indemnification and Insurance
    
    
    13Section 11 Infringement
    
    
    14Section 12 Confidentiality
    
    
    15Section 13 Effective Date, Term and Termination
    
    
    16Section 14 Miscellaneous Provisions
    
    
    1714.1 Force Majeure
    
    
    1714.2 Entire Agreement
    
    
    1714.3 R&D Agreement
    
    
    1714.4 Parties Independent
    
    
    1714.5 Severability
    
    
    1714.6 Governing Law
    
    
    1714.7 Assignment and Business Combination
    
    
    1814.8 Waivers and Amendments
    
    
    1814.9 Arbitration
    
    
    1814.10 Notices
    
    
    1814.11 Implementation
    
    
    1914.12 Parties Rights and Duties in Bankruptcy
    
    
    1914.13 Counterparts/Facsimile or Email Signatures
    
    
    19




---



##### 



ONCOGEL/GENEXOL
RESTATED LICENSE AND SUPPLY AGREEMENT
 
  RECITALS:
       1




---



##### 



Section 1 Definitions
  Affiliate
 Business Combination
     Confidential Information
 GMP-grade Genexol
 GMP list price
 Designated Territory One
 2




---



##### 



Designated Territory Two
 Effective Date
 EMEA
 FDA
 Five-Year Special Supply Period
 Genexol
 Licensed Patents
 License Waiver
 Net Sales
 Product
 Project
 Restated Agreement Date
 Technology
  Third Party
 Third Party Revenues
 Trademark
 3




---



##### 



Section 2 Product and Trademark License
      Section 3 Royalties
  4




---



##### 



* confidential treatment
requested 5




---



##### 



Section 4 Accounting Records
     Section 5 Product Development and Marketing
   * confidential treatment requested 6




---



##### 



* confidential treatment requested 7




---



##### 



Section 6 Genexol Supply
        * confidential treatment requested 8




---



##### 



9




---



##### 



* confidential treatment requested 10




---



##### 



(iii) * kg in the aggregate.
       * confidential treatment requested 11




---



##### 



Section 7 Technology Ownership and Maintenance
     Section 8 Representations and Warranties of MacroMed
    12




---



##### 



Section 9 Representations and Warranties of Genex
      Section 10 Indemnification and Insurance
  13




---



##### 



Section 11 Infringement
   14




---



##### 



Section 12 Confidentiality
   15




---



##### 



Section 13 Effective Date, Term and Termination
      16




---



##### 



Section 14 Miscellaneous Provisions
 Force Majeure. force majeure
 Entire Agreement.
 R&D Agreement.
 Parties Independent.
 Severability.
 Governing Law.
 17




---



##### 



Assignment and Business Combination.
      Waivers and Amendments.
 Arbitration.
 Notices.
 18




---



##### 



If to MacroMed:
    
    MacroMed, Inc.9520 South State StreetSandy, Utah 84070USAFax No.: (801) 565-8562Attn: Business DevelopmentIf to Genex:
    
    Samyang Genex Corporation263 Yeonji-Dong, Chongno-GuSeoul, Korea 110-725Fax No.: (822) 740-7988Attn: Bio Business Team
  Implementation.
 Parties Rights and Duties in Bankruptcy. et seq.
 Counterparts/Facsimile or Email Signatures.
 19




---



##### 



For MacroMed, Inc.
    
    
    
    For Samyang Genex Corporation/s/ Thomas Bergmann
    
    
    
    /s/ Ryang KimDate
    
    
    
    Date06/20/06
    
    
    
    07/03/06Thomas Bergmann
    
    
    
    President and CEOPresident and CEO
    
    
    
    Samyang Genex CorporationMacroMed, Inc.
 20